Donald Notman serves as the Chief Financial Officer at OCULAR THERAPEUTIX INC, a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. With over 25 years of experience in financial management and strategic planning, Notman has been instrumental in guiding OCULAR THERAPEUTIX INC through its growth and development phases. His expertise in the life sciences sector has helped the company navigate the complexities of bringing novel ophthalmic treatments to market. Prior to joining OCULAR THERAPEUTIX INC, Notman held several senior financial positions at various life sciences companies. He previously served as CFO at Achillion Pharmaceuticals, where he played a key role in the company's successful acquisition by Alexion Pharmaceuticals. Notman's career also includes significant stints at both large pharmaceutical companies and smaller biotech startups, giving him a well-rounded perspective on the industry. His academic background includes a Bachelor of Science in Business Administration from the University of Vermont and an MBA from the University of Connecticut. In his current role at OCULAR THERAPEUTIX INC, Donald Notman oversees all aspects of the company's financial operations, including budgeting, forecasting, and investor relations. He works closely with the executive team to develop and implement strategies that support the company's long-term growth objectives. Under his leadership, OCULAR THERAPEUTIX INC has successfully raised capital through multiple financing rounds and has made significant progress in advancing its pipeline of ophthalmic therapies. Notman's strategic vision and financial acumen have been crucial in positioning the company for continued success in the competitive field of biopharmaceuticals.